{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Sell LB"],"funding":["NINDS NIH HHS","National Institutes of Health"],"pagination":["108766"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8660955"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["235"],"pubmed_abstract":["Farnesol is a 15‑carbon organic isoprenol synthesized by plants and mammals with anti-oxidant, anti-inflammatory, and neuroprotective activities. We sought to determine whether farnesol treatment would result in protection against murine experimental autoimmune encephalomyelitis (EAE), a well-established model of multiple sclerosis (MS). We compared disease progression and severity in C57BL/6 mice treated orally with 100 mg/kg/day farnesol solubilized in corn oil to corn-oil treated and untreated EAE mice. Farnesol significantly delayed the onset of EAE (by ~2 days) and dramatically decreased disease severity (~80%) compared to controls. Disease protection by farnesol was associated with a significant reduction in spinal cord infiltration by monocytes-macrophages, dendritic cells, CD4<sup>"],"journal":["Clinical immunology (Orlando, Fla.)"],"pubmed_title":["Farnesol induces protection against murine CNS inflammatory demyelination and modifies gut microbiome."],"pmcid":["PMC8660955"],"funding_grant_id":["R15 NS107743"],"pubmed_authors":["Doyle WJ","Ramelow CC","Gibson KM","Kohl HM","Sell LB","Strawn KD","Hoffman K","Ochoa-Reparaz J","Bains JK","Kirby TO","Roullet JB","Hevrin T"],"additional_accession":[]},"is_claimable":false,"name":"Farnesol induces protection against murine CNS inflammatory demyelination and modifies gut microbiome.","description":"Farnesol is a 15‑carbon organic isoprenol synthesized by plants and mammals with anti-oxidant, anti-inflammatory, and neuroprotective activities. We sought to determine whether farnesol treatment would result in protection against murine experimental autoimmune encephalomyelitis (EAE), a well-established model of multiple sclerosis (MS). We compared disease progression and severity in C57BL/6 mice treated orally with 100 mg/kg/day farnesol solubilized in corn oil to corn-oil treated and untreated EAE mice. Farnesol significantly delayed the onset of EAE (by ~2 days) and dramatically decreased disease severity (~80%) compared to controls. Disease protection by farnesol was associated with a significant reduction in spinal cord infiltration by monocytes-macrophages, dendritic cells, CD4<sup>","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Feb","modification":"2025-04-19T17:57:52.273Z","creation":"2025-04-19T17:57:52.273Z"},"accession":"S-EPMC8660955","cross_references":{"pubmed":["34091018"],"doi":["10.1016/j.clim.2021.108766"]}}